Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Durable Response to Carboplatin, Etoposide, Nivolumab, and Ipilimumab in Metastatic High-Grade Neuroendocrine Carcinoma of the Gallbladder.

Pancreas - 1 Feb 2020

Chorath Jeena, Placencio-Hickok Veronica R, Guan Michelle, Nissen Nicholas, Kamrava Mitchell, Klempner Samuel J, Nassir Youram, Hendifar Andrew, Gong Jun

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carboplatin
Share to Carcinoma, Neuroendocrine
Share to Etoposide

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gallbladder

Share to Ipilimumab

Share to Ki-67 Antigen

Share to Nivolumab

Share to Retinoblastoma Binding Proteins

Source

Identifiers

PMID: 32049953
DOI: 10.1097/MPA.0000000000001480

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Durable Response to Carboplatin, Etoposide, Nivolumab, and Ipilimumab in Metastatic High-Grade Neuroendocrine Carcinoma of the Gallbladder.PMID 32049953Read ↗

Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan.Semantic proximity Read ↗

Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report.Semantic proximity Read ↗

Metastatic CDK12-Mutated Neuroendocrine Tumor of Lung Showed an Exceptional Response to Olaparib and Paclitaxel.Semantic proximity Read ↗

Successful Treatment of Metastatic Gallbladder Carcinoma with a High Tumor Mutational Burden Using Pembrolizumab.Semantic proximity Read ↗

Exceptional response to pembrolizumab in HER2-positive gallbladder carcinoma with high tumor mutational burdenSemantic proximity Read ↗

Sustained response on sequential anti-FGFR therapy in metastatic gall bladder cancer: a case report and literature review.Semantic proximity Read ↗

Exceptional Response to Pembrolizumab in HER2-Positive Gallbladder Carcinoma with High Tumor Mutational Burden.Semantic proximity Read ↗

Partial response in non-resectable adenosquamous carcinoma of the pancreas with high tumour mutation burden treated with gemcitabine, nab-paclitaxel and pembrolizumab.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.